Medpace Holdings, Inc. MEDP Cardiology — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medpace Holdings, Inc.'s cardiology — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medpace Holdings, Inc.'s cardiology — total revenue?
- Medpace Holdings, Inc. (MEDP) reported cardiology — total revenue of $80.21M in Q1 2026.
- How has Medpace Holdings, Inc.'s cardiology — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s cardiology — total revenue increased by 46.1% year-over-year, from $54.9M to $80.21M.
- What is the long-term trend for Medpace Holdings, Inc.'s cardiology — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s cardiology — total revenue has grown at a 20.3% compound annual growth rate (CAGR), from $121.55M to $254.84M.
- What does cardiology — total revenue mean?
- The total revenue earned from clinical trial and development services provided for cardiology-related projects.
- How do you interpret cardiology — total revenue?
- An increase indicates growing demand for the company's cardiology-focused clinical research services and successful project acquisition, while a decrease may signal reduced client spending or increased competition in this therapeutic niche.
- How does cardiology — total revenue compare across companies?
- Comparable to revenue metrics for specific therapeutic segments in other contract research organizations, often benchmarked against broader industry trends in cardiovascular clinical trial investment.